Form 8-K - Current report:
SEC Accession No. 0001558370-25-003036
Filing Date
2025-03-17
Accepted
2025-03-17 06:55:30
Documents
15
Period of Report
2025-03-17
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K plx-20250317x8k.htm   iXBRL 8-K 40197
2 EX-99.1 plx-20250317xex99d1.htm EX-99.1 191046
3 GRAPHIC plx-20250317xex99d1001.jpg GRAPHIC 5450
  Complete submission text file 0001558370-25-003036.txt   378528

Data Files

Seq Description Document Type Size
4 EX-101.SCH plx-20250317.xsd EX-101.SCH 3632
5 EX-101.LAB plx-20250317_lab.xml EX-101.LAB 16016
6 EX-101.PRE plx-20250317_pre.xml EX-101.PRE 10761
17 EXTRACTED XBRL INSTANCE DOCUMENT plx-20250317x8k_htm.xml XML 4864
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33357 | Film No.: 25742305
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)